Pharma major Lupin Ltd. announced that its subsidiary Lupin Pharmaceuticals Inc. had received final approval for its Lorazepam Oral Concentrate USP, 2 mg/mL from the US FDA to market a generic version of Lorazepam Intensol, 2 mg/mL, of Roxane Inc.
Lupin's Lorazepam Oral Concentrate USP, 2 mg/mL is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
As per IMS SAT September sales, Lorazepam Oral Concentrate had annual US sales of around $10.7 million.
At the BSE, Lupin closed Thursday's trading at Rs.594, down 0.21 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.